University of Utah researchers at the Pulst-Scoles Laboratory have discovered that reducing levels of the STAUFEN-1 protein ...

When brain cells die in diseases like ALS (amyotrophic lateral sclerosis) and frontotemporal dementia, they often activate a ...

There are hardly any drugs against ALS. A new study shows that a substance acting on the MAPK signaling pathway may be effective against the neurodegenerative disease: After treatment with trametinib, ...

Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.

An update from Pharmaust Limited ( ($AU:NUZ) ) is now available. Neurizon Therapeutics has provided a regulatory update on NUZ-001, its ...

The pathway leading to the telltale sign of ALS, protein aggregation in the cytoplasm of motor neurons, has been revealed. Researchers from the University of California – San Diego (CA, USA) have ...

Pictured are nuclei of induced pluripotent stem cell (iPSC)-derived motor neurons stained for contrast. The nucleus on the left has been treated with DMSO (control) and appears mostly blue. The ...

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers for ...

Clene (CLNN) announced that it recently received written guidance from the Division of Neurology 1, DN1, of the U.S. Food and Drug Administration regarding a potential accelerated approval pathway for ...

FDA recommends that Clene (CLNN) leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY ALS Platform Trial to support earlier presented ...